tiprankstipranks
Trending News
More News >
Innate Pharma (IPHA)
NASDAQ:IPHA
US Market

Innate Pharma (IPHA) Technical Analysis

Compare
116 Followers

Technical Sentiment

Overall Consensus
Buy
10Bullish
5Neutral
7Bearish
Technical Analysis Consensus
Buy
4Bullish
5Neutral
1Bearish
Moving Average Consensus
Neutral
6Bullish
0Neutral
6Bearish
Innate Pharma’s (IPHA) Moving Averages Convergence Divergence (MACD) indicator is 0.01, suggesting Innate Pharma is a Buy.
Innate Pharma’s (IPHA) 20-Day exponential moving average is 2.15, while Innate Pharma’s (IPHA) share price is $2.17, making it a Sell.
Innate Pharma’s (IPHA) 50-Day exponential moving average is 2.10, while Innate Pharma’s (IPHA) share price is $2.17, making it a Buy.

Innate Pharma (IPHA) Pivot Points

Jun 08, 2025, 06:05 AM
Name
S3
S2
S1
Pivot Points
R1
R2
R3
Classic
2.07
2.10
2.12
2.16
2.18
2.21
2.23
Fibonacci
2.10
2.12
2.14
2.16
2.18
2.19
2.21
Pivot points are a technical analysis tool used by traders to identify potential support and resistance levels in financial markets. Pivot points are calculated based on the previous day's high, low, and close prices, and are used to help traders identify levels at which the price may reverse or continue to trend.

Innate Pharma (IPHA) Moving Averages

Jun 08, 2025, 06:05 AM
Period
Simple
Exponential
MA5
2.15Sell
2.15Sell
MA10
2.16Sell
2.15Sell
MA20
2.17Sell
2.15Sell
MA50
2.06Buy
2.10Buy
MA100
2.01Buy
2.05Buy
MA200
2.00Buy
2.05Buy
Innate Pharma’s (IPHA) 10-Day exponential moving average is 2.15, while Innate Pharma’s (IPHA) share price is $2.17, making it a Sell.
Innate Pharma’s (IPHA) 100-Day exponential moving average is 2.05, while Innate Pharma’s (IPHA) share price is $2.17, making it a Buy.
Innate Pharma’s (IPHA) stock price is $2.17 and Innate Pharma’s (IPHA) 50-day simple moving average is 2.06, creating a Buy signal.
Innate Pharma’s (IPHA) stock price is $2.17 and Innate Pharma’s (IPHA) 100-day simple moving average is 2.01, creating a Buy signal.
Innate Pharma’s (IPHA) stock price is $2.17 and Innate Pharma’s (IPHA) 200-day simple moving average is 2.00, creating a Buy signal.

Innate Pharma (IPHA) Technical Indicators

Jun 08, 2025, 06:05 AM
Name
Value
Implied Action
RSI (14)
50.93
Neutral
STOCH (9,6)
47.50
Neutral
STOCHRSI (14)
47.72
Neutral
MACD (12,26)
0.01
Buy
ADX (14)
11.22
Buy
Williams %R
-40.64
Buy
CCI (14)
-53.81
Neutral
ATR (14)
0.11
-
Ultimate Oscillator
56.22
Neutral
ROC
1.90
Buy
Innate Pharma’s (IPHA) Relative Strength Index (RSI) is 50.93, creating a Neutral signal.
Innate Pharma’s (IPHA) Trend Strength Indicator (ADX) is 11.22, creating a Buy signal.
Innate Pharma’s (IPHA) Commodity Channel Index (CCI) is -53.81, creating a Neutral signal.
Innate Pharma’s (IPHA) Price Rate of Change (ROC) is 1.90, creating a Buy signal.

FAQ

Is IPHA a Buy, Hold, or Sell?
Based on IPHA’s technical indicators, IPHA is a Buy.
    What is IPHA’s RSI (14)?
    IPHA’s RSI (14) is 50.93, which suggests IPHA is a Neutral.
      What is IPHA’s MACD?
      IPHA’s MACD is 0.01, which suggests IPHA is a Buy.
        What is IPHA’s 5-day moving average?
        IPHA’s 5-day moving average is 2.15, which suggests IPHA is a Sell.
          What is IPHA’s 20-day moving average?
          IPHA 20-day moving average is 2.17, which suggests IPHA is a Sell.
            What is IPHA’s 50-day moving average?
            IPHA’s 50-day moving average is 2.06, which suggests IPHA is a Buy.
              What is IPHA’s 200-day moving average?
              IPHA’s 200-day moving average is 2.00, which suggests IPHA is a Buy.
                What is IPHA’s Williams % R (14)?
                IPHA’s Williams % R (14) is -40.64, which suggests IPHA is a Buy.
                  What is IPHA’s CCI (14)?
                  IPHA’s CCI (14) is -53.81, which suggests IPHA is a Neutral.
                    What am I Missing?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis